A significant proportion of neurology and neuropsychiatry patients are refractory and do not respond to treatment. Currently, the response of these patients to medication is evaluated only on the basis of symptoms. Drug response varies between individuals due to factors such as genetic structure and metabolic rate (polymorphism). Depending on the DNA structure of individuals, some do not activate some drugs at all, some metabolize them fast and some metabolize them slowly, so the response to drugs and treatment varies between individuals. The patient's response to the drug should be known and the dose should be adjusted according to this response. Recent developments in the world of medicine and biology bring the necessity of individualization of treatment (individual response to medication and treatment) to the agenda.
KİMER (Personalized Treatment Application and Research Center) is a center that provides preliminary information to the individual and the physician about possible polymorphisms by measuring the individual's response to the drug through Drug Blood Level Monitoring (TDM) and helps to regulate pharmacotherapy.
Objectives of the Center's practices:
- Ensuring that the right drug is taken at the right dose by monitoring drug blood levels and preventing the individual's non-response to treatment or exposure to drug toxicity
- To ensure that genotyping or phenotyping studies are carried out by evaluating the differences in the individual's response to the drug
- To carry out phenotyping studies to determine the pharmacokinetic phenotype of the individual at that moment.
We invite scientists and private and legal entities who want to work on any subject that will individualize treatment and make it personalized to work together in this field.
Korkut ULUCAN
Kimer Manager